We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cancer Therapeutics CRC Enters Collaboration with Major US Academic Medical Center to discover and develop novel drugs for the treatment of cancer
News

Cancer Therapeutics CRC Enters Collaboration with Major US Academic Medical Center to discover and develop novel drugs for the treatment of cancer

Cancer Therapeutics CRC Enters Collaboration with Major US Academic Medical Center to discover and develop novel drugs for the treatment of cancer
News

Cancer Therapeutics CRC Enters Collaboration with Major US Academic Medical Center to discover and develop novel drugs for the treatment of cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cancer Therapeutics CRC Enters Collaboration with Major US Academic Medical Center to discover and develop novel drugs for the treatment of cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Melbourne, Australia,October 05, 2009 / b3c newswire / - Cancer Therapeutics CRC Pty Ltd, Melbourne, Australia (CTx) today announced a collaboration with Duke University, North Carolina, USA (Duke) to discover and develop new drugs for the treatment of many forms of cancer, based on research undertaken by the laboratory of Duke Professor Patrick Casey.

Professor Casey and his team at Duke have been investigating lipid signaling pathways and the role of lipid metabolising enzymes in cancer for many years and have developed a series of promising new inhibitors of these enzymes. CTx has taken an exclusive license to these inhibitors and will initiate a drug development program to bring these early stage compounds toward the clinic.
This adds to CTx’s international collaborations and was greatly facilitated by CTx’s commercial partner, Cancer Research Technology Ltd of the UK and its US subsidiary, Cancer Research Technology Inc.

CTx’s CEO, Tony Evans commented that collaborating with an academic medical center of Duke’s caliber is a major expansion of CTx’s capabilities in partnering with overseas cancer researchers in order to source the most promising novel targets for CTx’s drug discovery projects.

Advertisement